



Resolution n°23-2022-e

Extension of investments in Unitaid's COVID-19 Test-and-Treat and Medical Oxygen Portfolios

Recalling the Executive Board's decision EB35/2020/R4, which set out the mandate and process for Unitaid's involvement in the ACT-A and in doing so, allowed the Secretariat to rapidly respond to the acute phase of the COVID-19 pandemic by establishing a comprehensive portfolio of investments in both COVID-19 Test-and-Treat and Medical Oxygen, through the reprogramming of existing grants with Board-approved implementers;

Recognizing the impact achieved through these investments, together with the need to provide implementers with the time necessary to complete originally planned activities, as well as support transition of implemented interventions, with a view to responding to increased demands for integrated and sustainable measures to address COVID-19 and oxygen access within routine primary health care; and

Acknowledging the report by the Secretariat, together with the recommendations of the Secretariat and the Proposal Review Committee;

The Board authorizes the Executive Director to sign legal amendments extending the duration of Unitaid's **COVID-19 Test-and-Treat** investments with the following implementers on a no-cost basis:

- **Aurum**, extended to 31 March 2023;
- **FIOTEC**, extended to 31 October 2023; and
- **IS Global**, extended to 31 March 2023;

The Board authorizes the Executive Director to sign legal amendments increasing budget ceilings and extending the duration of Unitaid's **COVID-19 Test-and-Treat** investments with the following implementers, up to the amounts specified:


- **CHAI**, extended to 30 November 2023 with a budget increase of up to **US\$ 4,806,203**;
- **EGPAF**, extended to 30 September 2023 with a budget increase of up to **US\$ 4,000,000**;
- and
- **PSI**, extended to 30 September 2023 with a budget increase of up to **US\$ 1,000,000**.

The Executive Board authorizes the Executive Director to sign legal amendments extending the duration of Unitaid's **Medical Oxygen** investments with the following implementers on a no-cost basis:

- **ALIMA**, extended to 30 June 2023;

- **PIH**, extended to 30 September 2023;
- **WHE**, extended to 31 December 2023;
- **CHAI**, Output 9 extended to 31 July 2023; and Output 11 extended to 31 December 2023.

The Board notes that further extensions beyond the specified dates may prove necessary, to ensure the responsible transition and closure of these investments. The Board therefore authorizes the Executive Director at his discretion to further extend any of the investments listed in this decision, on a no-cost basis. up to 31 December 2023.



Marisol Touraine
Chair of the Unitaid Executive Board

Date: 19 December 2022